Logo image of TSVT

2SEVENTY BIO INC (TSVT) Stock Price, Quote, News and Overview

NASDAQ:TSVT - Nasdaq - US9013841070 - Common Stock - Currency: USD

5  +0.02 (+0.4%)

After market: 5 0 (0%)

TSVT Quote, Performance and Key Statistics

2SEVENTY BIO INC

NASDAQ:TSVT (5/2/2025, 8:26:33 PM)

After market: 5 0 (0%)

5

+0.02 (+0.4%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.3
52 Week Low2.29
Market Cap261.70M
Shares52.34M
Float48.67M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08/bmo
IPO10-18 2021-10-18


TSVT short term performance overview.The bars show the price performance of TSVT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

TSVT long term performance overview.The bars show the price performance of TSVT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40

The current stock price of TSVT is 5 USD. In the past month the price increased by 0.6%. In the past year, price increased by 5.04%.

2SEVENTY BIO INC / TSVT Daily stock chart

TSVT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About TSVT

Company Profile

TSVT logo image 2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.

Company Info

2SEVENTY BIO INC

60 Binney Street

Cambridge MASSACHUSETTS US

Employees: 274

TSVT Company Website

TSVT Investor Relations

Phone: 13394999300

2SEVENTY BIO INC / TSVT FAQ

What is the stock price of 2SEVENTY BIO INC today?

The current stock price of TSVT is 5 USD. The price increased by 0.4% in the last trading session.


What is the ticker symbol for 2SEVENTY BIO INC stock?

The exchange symbol of 2SEVENTY BIO INC is TSVT and it is listed on the Nasdaq exchange.


On which exchange is TSVT stock listed?

TSVT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for 2SEVENTY BIO INC stock?

9 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5. Check the 2SEVENTY BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is 2SEVENTY BIO INC worth?

2SEVENTY BIO INC (TSVT) has a market capitalization of 261.70M USD. This makes TSVT a Micro Cap stock.


How many employees does 2SEVENTY BIO INC have?

2SEVENTY BIO INC (TSVT) currently has 274 employees.


What are the support and resistance levels for 2SEVENTY BIO INC (TSVT) stock?

2SEVENTY BIO INC (TSVT) has a support level at 4.99 and a resistance level at 5.01. Check the full technical report for a detailed analysis of TSVT support and resistance levels.


Is 2SEVENTY BIO INC (TSVT) expected to grow?

The Revenue of 2SEVENTY BIO INC (TSVT) is expected to grow by 42.31% in the next year. Check the estimates tab for more information on the TSVT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy 2SEVENTY BIO INC (TSVT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does 2SEVENTY BIO INC (TSVT) stock pay dividends?

TSVT does not pay a dividend.


When does 2SEVENTY BIO INC (TSVT) report earnings?

2SEVENTY BIO INC (TSVT) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of 2SEVENTY BIO INC (TSVT)?

2SEVENTY BIO INC (TSVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).


What is the Short Interest ratio of 2SEVENTY BIO INC (TSVT) stock?

The outstanding short interest for 2SEVENTY BIO INC (TSVT) is 7.77% of its float. Check the ownership tab for more information on the TSVT short interest.


TSVT Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TSVT. When comparing the yearly performance of all stocks, TSVT is one of the better performing stocks in the market, outperforming 96.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TSVT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TSVT. While TSVT seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TSVT Financial Highlights

Over the last trailing twelve months TSVT reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 72.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -11.94%
ROE -27.16%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.67%
Sales Q2Q%-72.61%
EPS 1Y (TTM)72.14%
Revenue 1Y (TTM)-62.28%

TSVT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 49% to TSVT. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 58.41% and a revenue growth 42.31% for TSVT


Ownership
Inst Owners89.58%
Ins Owners4.73%
Short Float %7.77%
Short Ratio2.49
Analysts
Analysts48.89
Price Target5.1 (2%)
EPS Next Y58.41%
Revenue Next Year42.31%